MDD Clinical Trial
Official title:
CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial
The goal of this randomized placebo controlled trial is to compare the antidepressant effect of a single oral dose of psilocybin 25 mg compared to 1 mg in 100 patients with cancer related major depressive disorder. The main question it aims to answer is: The primary objective of this study is to evaluate the efficacy of a single 25 mg oral dose of psilocybin for major depressive disorder (MDD) compared to an active placebo (psilocybin 1 mg) assessed as the difference between groups in changes in depressive symptoms, in the following Population: 20-80 (inclusive) years old, current depressive episode (according to Patient Health Questionnaire (PHQ-9) ≥10), >1 month after cancer diagnosis, with at least 12 months of life expectancy, willingness to abstain from other psychotherapeutic or antidepressant treatments during the study (wash out time 5 half-lives).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04482296 -
Effect of Zinc Supplementation on Depression in SSRI-treated Major Depressive Disorder Patients
|
N/A | |
| Recruiting |
NCT04071886 -
Effect of Short-Term Mindfulness-Based Training For Major Depression Disorder: An Eye-Tracking Study
|
N/A | |
| Completed |
NCT04076644 -
Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder
|
N/A | |
| Completed |
NCT05528315 -
SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT05437588 -
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
|
N/A | |
| Recruiting |
NCT06095778 -
rTMS Therapy for Treatment-Resistant Depression With Different Targets Guided by pBFS
|
N/A | |
| Active, not recruiting |
NCT05657691 -
Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)
|
Phase 2 | |
| Completed |
NCT02013609 -
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
|
Phase 3 | |
| Completed |
NCT02339285 -
Transcranial Alternating Current Stimulation for Major Depressive Disorder
|
N/A | |
| Recruiting |
NCT03971305 -
A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL
|
||
| Recruiting |
NCT05169346 -
Neurofeedback to Treat Depression
|
N/A | |
| Completed |
NCT01344733 -
A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD)
|
N/A | |
| Completed |
NCT04268316 -
Virtual Reality Behavioral Activation: An Intervention for Major Depressive Disorder
|
N/A | |
| Active, not recruiting |
NCT01557946 -
Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression
|
Phase 2 | |
| Recruiting |
NCT01501812 -
Evaluation of Generalization Paradigm Patterns Among Different Psychiatric Disorders
|
N/A | |
| Completed |
NCT04880460 -
Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder Patients
|
Phase 2 | |
| Completed |
NCT04226352 -
Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder
|
Phase 1 | |
| Recruiting |
NCT03754712 -
Effect of Vitamin D Administration Along With SSRIs in Patients With Major Depressive Disorder
|
N/A | |
| Recruiting |
NCT02669030 -
A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia
|
Phase 4 | |
| Completed |
NCT03994081 -
Mechanism of Action of tACS for the Treatment of MDD
|
N/A |